Inpharmatica Ltd. 60 Charlotte Street London W1P 2AX United Kingdom Phone: +49 (0) 207 631 4644 Fax: +49 (0) 207 631 4844 Management Malcolm Weir, CEO Sean Hird, chief operating officer Janet Thornton, founder and chief scientific officer John Overington, director of drug discovery Mark Swindells, scientific director David Ricketts, vice president, business development Overview Inpharmatica Ltd. was founded in 1998. It develops and markets information-based solutions for

genOway 46 all e d Italie 69007 Lyon, France Phone: +33 (0) 4 72 72 87 17 Fax: +33 (0) 4 72 72 87 19 www.genoway.com Management Alexandre Fraichard, CEO Gilles de Poncins, executive vice president Overview Founded in March 1999, Lyon, France-based genOway is a functional genomics company developing tailor-made research models such as transgenic rodents (mice and rats) and in vitro differentiation systems based on its embryonic stem (ES) cells knowledge. The company s main

Genfit SA Parc Eurasant 885, Avenue Eug ne Avin e 59120 Loos, France Phone: +33 (0) 3 20 16 40 00 Fax : +33 (0) 3 20 16 40 40 www.genfit.com Management Jean-Charles Fruchart, founder and chairman Jean-Fran ois Mouney, founder and CEO Bart Staels, vice president, research Florence S journ , vice president, business development Dean Hum, director, genomics Jamila Fruchart-Najib, director, biochemistry and proteomics Karine Bertrand-Caumont, director, chemistry Overview

GenProfile AG Robert-Rossle-Str. D-13125 Berlin-Buch Germany Phone: +49 (30) 94 89 21 50 Fax: +49 (30) 94 89 21 51 www.genprofile.com Management Margret Hoehe, founder and head of the Genome Research Group at the Max Delbr ck Center for Molecular Medicine Rolf Zettl, founder and former managing director of the Resource Center of the German Human Genome Project Overview Privately held GenProfile AG was founded in 1998 as the largest commercial spin-off of the German Human

GeneTrace Systems Inc. 1401 Harbor Bay Parkway Alameda, CA 94502 Phone: (510) 748-6000 Fax: (510) 748-6001 www.genetrace.com Management George LaMotte, CEO Leslie Browne, chief operating officer Frank Eeckman, senior director, information technology Ron FitzGerald, senior director, operations James Keck, senior director of drug discovery Joseph Monforte, chief scientific officer Maria Straatmann, business development Roger Walker, director, biotechnology research and

Galapagos Genomics N.V. Generaal De Wittelaan L11 A3 B 2800 Mechelen Belgium Tel: +32 15 34 29 00 Fax: +32 15 34 29 01 www.galapagosgenomics.com Management Onno van de Stolpe, managing director Dirk Pollet, vice president, business development Helmuth van Es, director, cellular and molecular biology Peter Tomme, director, laboratory Philippe Kerremans, director, information technology Overview In 1999, Crucell NV (formerly IntroGene B.V.) and Tibotec N.V. created

Stock Performances, Market Capitalization Company 12/31/99 12/31/00 Chg (%) Shares Out (M) Mkt. Cap (M) Affymetrix Inc. (NasdaqAFFX) 169.6875 74.4375 -56.13 55.6 $4,135 ARIAD Pharmaceuticals Inc. (NasdaqARIA) 2.8125 4.75 68.89 27.1 $129 Aurora BioSciences Corp. (NasdaqABSC) 26.5 31.4375 18.63 20.6 $647 Celera Genomics (NYSECRA) 149 36.125 -75.76 60.8 $2,196 CuraGen Corp. (NasdaqCRGN) 69.75 27.3125 -60.84 38.9 $1,063 deCODE genetics Inc.1 (NasdaqDCGN) 18 10

By Randall Osborne West Coast Editor Tempting as it may be to call proteomics ?an idea whose time has come? with the mapping of the human genome, analysts say investors might do well to keep in mind that the science was snickered away as impractical five years ago. And, despite all the activity, proteomics faces big challenges today. ?Conceptually, everyone realizes the genes aren?t interesting, in and of themselves,? said Jon Alsenas, portfolio manager and managing director of ING Furman

Genomics Collaborations with Non-Profit Organizations in 2000 Company University/Non-Profit [Scientist] Type of Agreement Product Area Details (Month) Acadia PharmacoGenomics (subsidiary of Acadia Pharmaceuticals Inc.) Karolinska Institute CMM (Sweden) Research collaboration Pharmacogenomic project in antipsychotic field Collaboration will compare two patient populations: a group that responds to the traditional antipsychotic haloperidol, and a group that does not respond to

By Randall Osborne West Coast Editor By late 2000, the genomics boom had become more of a dull, persistent thump, like the heartbeat of something very much alive, but not yet up and walking around. Early hysteria, which had begun the year before, over the mapping of the human genome had subsided and - with most of the genome in hand - companies (as well as investors) found themselves wondering what to do next. The magic of knowing turned out to be not much magic at all. If, as the last

By Kim Coghill Washington Editor The nation?s first-ever standards for protecting the privacy of Americans? personal health records are a step in the right direction, biotechnology industry leaders said. But approval of the standards likely is only the first move Congress will have to take to protect the public. The standards protect personal health information and medical records maintained by health-care providers, hospitals, health plans and insurers. And they protect against unauthorized

West Coast Editor During the now historical (and hysterical) heyday of dot-com firms, those times when data-mad investors laid massive amounts of cash on Internet stocks, the apparent best way for biotechnology to get a piece of action was by hooking up by any means necessary to the click on it revolution. Bioinformatics seemed just the ticket. Many people didn t know what bioinformatics meant, but figured it couldn t be far afield from the bits-and-bytes gold mine out of which others had

Vysis Inc. 3100 Woodcreek Drive Downers Grove, IL 60515-5400 Phone: (630) 271-7000, Toll Free: (800) 553-7042 Fax: (630) 271-7138 www.vysis.com Management John Bishop, president and CEO John Sluis, senior vice president and chief financial officer Russel Enns, vice president, regulatory affairs Steven Seelig, vice president, research and development and chief medical officer Robert Koska, vice president, sales and marketing William Murray, vice president, general counsel and

Variagenics Inc. 60 Hampshire Street Cambridge, MA 02139-1562 Phone: (617) 588-5300 Fax: (617) 588-5399 www.variagenics.com Management Taylor Crouch, president and CEO Bruce Maloff, executive vice president, commercial operations Colin Dykes, vice president, research and genomics Rick Shea, vice president, chief financial officer and treasurer Anne Bailey, vice president, diagnostics Vincent Stanton Jr., vice president and principal scientist R. Mark Adams, senior director

SignalGene Inc. 8475 Christophe-Colomb Avenue Suite 1000 Montreal, Quebec, H2M 2N9 Canada Phone: (514) 850-2400 Fax : (514) 850-2424 www.signalgene.com Management Michael Dennis, chairman, president and CEO Lucie St-Georges, vice president, finance and chief financial officer Pierre Chr tien, vice president, technology and chief technology officer Lawrence T. Malek, vice president, target discovery Overview In 1999, Alg ne Biotechnologies Corp., of Montreal, changed its